University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 32 of 35
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
NCT00365144
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00313599
Chronic Sildenafil for Severe Diaphragmatic Hernia
NCT00133679
Chromium and Insulin Resistance
NCT00846248
Smoking Treatment in HIV Clinical Care Settings
NCT00297453
Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
NCT00221338
Potassium Citrate to Prevent Age Related Bone Loss
NCT00282126
Quality Improvement in Stroke Prevention (QUISP)
NCT00328640
Integrating Buprenorphine Into the SFGH AIDS Program
NCT00263458
Drug Interaction Study Between Antimalarial and Anti-HIV Medications
NCT00266058
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT00293332
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
NCT00293423
Paleolithic Diet and Exercise Study
NCT00360516
Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women
NCT00306007
Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft
NCT00488358
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
NCT00290719
Mild Pulmonary Function Changes With Transfusion
NCT00681954
Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM
NCT00187902
Trial of Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Abortion
NCT00235534
The Efficacy of the HIV/AIDS Symptom Management Manual
NCT00241202
C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough
NCT00221351
The ICU Care Knowledge Study
NCT00305981
RESPeRATE for Treatment of Hot Flashes
NCT00283231
Yoga for Treatment of Hot Flashes
NCT00283205
Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin
NCT00187707
Specialized Cognitive-Behavioral Counseling Intervention to Reduce HIV Transmission Risk Behavior in HIV-Infected Men
NCT00218712
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
NCT01167543
Nicotine Replacement and Counseling In Adolescents
NCT00625794
Doctor-Patient Communication in Spanish
NCT00187785
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
NCT00511550
Trial of Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion
NCT00235547
Optimal Approach for Analysis of Case-Control Genetic Association Studies
NCT00241709
Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study
NCT00361400
Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules
NCT00316823
The Young Woman's Reach Project: Trial of an Intervention to Impact Contraceptive Behavior, Unintended Pregnancy, and Sexually Transmitted Infections (STIs) Among Adolescent Females
NCT00230880
Effectiveness of Using Reduced Nicotine Cigarettes in Men and Women Smokers to Combat Nicotine Addiction
NCT00264342
Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism
NCT00273650
Histoblood Group Antigens as a Risk Factor of Asthma
NCT00201266
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
NCT00227617
Biomarkers in Obstructive Sleep Apnea Surgery
NCT00507078
Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
NCT00187577
Ultrasound Guidance for Intravenous Cannulation in Emergency Department Patients.
NCT00692549
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
NCT00706966
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
NCT00313534
Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV
NCT00271856
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
NCT00293319
CJD (Creutzfeldt-Jakob Disease) Quinacrine Study
NCT00183092
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease
NCT00295971
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
NCT00278434
Biofeedback Treatment for Functional Constipation
NCT00502957
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.